Breast Cancer Clinical Trials in Detroit

Showing 181-200 of 609 trials

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

NCT02784795

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.

Solid TumorBreast CancerColon Cancer+2 more

Eli Lilly and Company94 participantsStarted Nov 2016

Miami, Florida, United States • Detroit, Michigan, United States • New York, New York, United States +8 more locations

Active Not RecruitingPhase 1< 1 mile

A Study of ADRX-0706 in Select Advanced Solid Tumors

NCT06036121

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.

Solid TumorsTriple Negative Breast Cancer (TNBC)Urothelial Cancer+1 more

Adcentrx Therapeutics144 participantsStarted Sep 2023

Los Angeles, California, United States • Los Angeles, California, United States • St. Petersburg, Florida, United States +18 more locations

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

A Study of ADRX-0706 in Select Advanced Solid Tumors

Breast Cancer Trials in Other Cities

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

MGC018 With or Without MGA012 in Advanced Solid Tumors

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

Proton Radiation for Stage II/III Breast Cancer

MarginProbe 2.0 Data Collection Protocol

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Other Conditions in Detroit